AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12086367
Drug: Combination montelukast
RxNorm normalized name: montelukast, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination montelukast 10 mg and loratadine 10 mg
Trial: 12086367
Drug: Montelukast/loratadine vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast/loratadine vs each therapy alone
Trial: 9793700
Drug: s.c. naratriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. naratriptan 1 mg
Trial: 9793700
Drug: s.c. naratriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. naratriptan 5 mg
Trial: 9793700
Drug: s.c. naratriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. naratriptan 10 mg
Trial: 7629756
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms Atrial natriuretic hormone (ANH)
Trial: 351073
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg on two consecutive days each week for six months)
Trial: 31130273
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block (ACB) with ropivacaine 0.5%, 20 ml
Trial: 31130273
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) with ropivacaine 0.5%, 20 ml
Trial: 24828126
Drug: Conventional hope
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hope box integrated into VA behavioral health treatment
Trial: 21106046
Drug: Brimonidine twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine twice daily (BID)
Trial: 21106046
Drug: Brimonidine three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine three times daily (TID)
Trial: 19765430
Drug: Basiliximab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (2 doses)
Trial: 19765430
Drug: Daclizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (5 doses)
Trial: 16751166
Drug: Intra-articular hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hylan G-F 20
Trial: 11063767
Drug: Ketoprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (100 mg in 50 mL saline, warmed to 37 degrees C)
Trial: 11063767
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL distilled water in 50 mL saline)
Trial: 9093709
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5-fluorouracil and levamisole)
Trial: 8096373
Drug: Zidovudine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (two daily doses)
Trial: 3532335
Drug: Low-dose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (1 MU/m2) subcutaneous (SC) treatment 5 days per week, every other week, for eight weeks
Trial: 3532335
Drug: High-dose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (50 MU/m2) intravenous (IV) treatment 5 days per week, every other week, for eight weeks
Trial: 3532335
Drug: High-dose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (30 MU/m2) intravenous (IV) treatment three times per week for eight weeks
Trial: 3532335
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of alpha interferon and chemotherapeutic agents (VP-16 and vinblastine)
Trial: 19059736
Drug: Classroom‐Centered (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom‐Centered (CC) intervention
Trial: 12723461
Drug: RWJ 67657
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ 67657 (10 mg/kg)
Trial: 12723461
Drug: RWJ 67657
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ 67657 (20 mg/kg)
Trial: 12723461
Drug: RWJ 67657
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ 67657 (0.25-30 mg/kg)
Trial: 11730394
Drug: Unopposed micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d)
Trial: 11730394
Drug: Unopposed micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who did not receive lipid‐lowering medication
Trial: 11730394
Drug: Placebo among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo among women who did not receive lipid‐lowering medication
Trial: 11730394
Drug: Unopposed micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who took lipid‐lowering medication
Trial: 11730394
Drug: Placebo among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo among women who took lipid‐lowering medication
Trial: 9213324
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 8 courses
Trial: 9213324
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Trial: 9213324
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses with G-CSF (filgrastim) followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Trial: 2455105
Drug: Lisinopril, 20
RxNorm normalized name: Lisinopril, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril, 20 mg
Trial: 2455105
Drug: Nifedipine and
RxNorm normalized name: nifedipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine and Lisinopril combination
Trial: 29549005
Drug: Nitrate supplement
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplement group (beetroot juice)
Trial: 25684765
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infliximab (IFX) therapy
Trial: 25684765
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg or 10 mg/kg infliximab (IFX) therapy
Trial: 3301505
Drug: Diltiazem (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (300 mg/die)
Trial: 3301505
Drug: Nifedipine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (50 mg/die)
Trial: 3301505
Drug: Verapamil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (400 mg/die)
Trial: 29911074
Drug: 28-day miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28-day miltefosine monotherapy
Trial: 29911074
Drug: 11-day combination
RxNorm normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB)
Trial: 29911074
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (L-AMB)
Trial: 25142196
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) combined with antidepressant medication (ADM)
Trial: 25142196
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (ADM) alone
Trial: 23363666
Drug: Daily bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bathing in chlorhexidine gluconate (CHG) 2%
Trial: 20092709
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenous drip, once every 12 hours)
Trial: 20092709
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg intravenous injection, once every 8 hours)
Trial: 20092709
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Erythromycin and Metoclopramide)
Trial: 17932089
Drug: Full-CAT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-CAT (Cognitive Adaptation Training focused on community adaptation including grooming, care of living quarters, leisure skills, social and role performance, and medication adherence)
Trial: 17932089
Drug: Pharm-CAT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharm-CAT (Cognitive Adaptation Training focused only on medication and appointment adherence)
Trial: 7648374
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg/d
Trial: 2670634
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day nimesulide
Trial: 11319723
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol intake of up to approximately 800 mg/day
Trial: 11319723
Drug: Insulin-resistant women
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant women
Trial: 21775510
Drug: Insulin-sensitive women
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive women
Trial: 31208472
Drug: Water for
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for injection (WFI)
Trial: 23359970
Drug: Fuzheng Fujia
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.2 g in 100 mL / DIDECYLDIMONIUM CHLORIDE 0.6 g in 100 mL TOPICAL SPRAY [FVJIA disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Fujia Mixture (FFM), 3 times daily for one month as 1 therapeutic course, in addition to Levothyroxine Sodium Tablet (LST) as routine treatment.
Trial: 23359970
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine Sodium Tablet (LST) as routine treatment.
Trial: 19852964
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a plus ribavirin (HCV RNA >500,000 IU/mL)
Trial: 19852964
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b plus ribavirin (HCV RNA >500,000 IU/mL)
Trial: 19852964
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Trial: 19852964
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Trial: 18066962
Drug: Thrombophilia screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombophilia screening protocol including hereditary thrombophilic disorders, antiphospholipid antibodies, and hyperhomocysteinemia.
Trial: 1931532
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (therapeutic dosage, serum levels of 10-20 micrograms/ml) for two months
Trial: 7145250
Drug: Clonidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.4 mg
Trial: 21126295
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (all-in-one self-etch adhesive; 3M ESPE) after water cleansing
Trial: 12117084
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium 4% nasal solution
Trial: 2793699
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose plus electrolytes (D5W) infusion for 48 hours
Trial: 669542
Drug: Benzopyrone preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzopyrone preparation (Venalot)
Trial: 669542
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (analgesic only)
Trial: 27831502
Drug: Pertuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab and trastuzumab with chemotherapy (paclitaxel, epirubicin, cyclophosphamide)
Trial: 17400953
Drug: Commit (medicinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commit (medicinal nicotine lozenge)
Trial: 8385284
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 20 mg
Trial: 7589046
Drug: Combined atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined atenolol 100 mg and nifedipine retard 20 mg
Trial: 7589046
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (active control)
Trial: 7468987
Drug: Pentazocine (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (higher dose)
Trial: 7468987
Drug: Pentazocine (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (lower dose)
Trial: 31274119
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (4 doses of Norfloxacin 400mg, twice a day for two days)
Trial: 27898215
Drug: Aggressive drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive drainage (daily drainage)
Trial: 23218591
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (15 min prior to radiation)
Trial: 22072355
Drug: Pre-surgical dietetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-surgical dietetic guidance and intravenous fluids for malnourished patients (DNS)
Trial: 19698938
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) with medication
Trial: 19698938
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) without medication
Trial: 11352879
Drug: Prolonged antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antiplatelet therapy (6 months of clopidogrel and aspirin)
Trial: 11352879
Drug: Active gamma‐radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gamma‐radiation treatment (1 month of antiplatelet therapy)
Trial: 11352879
Drug: Placebo historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo historical control group (1 month of antiplatelet therapy)
Trial: 3622314
Drug: Controlled-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide 5-mononitrate 60 mg once daily
Trial: 3622314
Drug: Controlled-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide 60 mg once daily
Trial: 3622314
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of isosorbide 20 mg 3 times daily
Trial: 1982280
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg epinastine
Trial: 1982280
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg epinastine
Trial: 1982280
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg epinastine
Trial: 26561784
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g bioactive collagen peptides (BCP) daily for 6 months
Trial: 19808198
Drug: MAGE‐A3 antigen‐specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE‐A3 antigen‐specific cancer immunotherapeutic (ASCI) agents
Trial: 17582289
Drug: MPO level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPO level > or = 62.9 AUU/L
Trial: 17582289
Drug: MPO level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPO level when TnI <= 0.05 ng/ml
Trial: 15364316
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo with open-label antihypertensive therapy)
Trial: 12389143
Drug: Gabapentin 2000
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 2000 mg/day
Trial: 9661119
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg recombinant human growth hormone (rhGH)
Trial: 9661119
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg recombinant human growth hormone (rhGH)
Trial: 23425012
Drug: Dapagliflozin 2.5
RxNorm normalized name: dapagliflozin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 2.5 to 5 mg
Trial: 17377401
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) - 2 puffs administered at 0, 20, 40 min
Trial: 17377401
Drug: Terbutaline (T)
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (T) - 2 puffs administered at 0, 20, 40 min
Trial: 15188805
Drug: Phenobarbital 20
RxNorm normalized name: phenobarbital 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 20 mg/kg i.v. within first six hours of life
Trial: 11683930
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus AMPC 750 mg and CAM 200 mg b.i.d. (Group B-LAC200)
Trial: 11683930
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg, AMPC 750 mg and CAM 400 mg b.i.d. (Group C-LAC400)
Trial: 11683930
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg twice a day (Group A-LPZ-only)
Trial: 2917701
Drug: Gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (600 mg twice daily) + Lovastatin (20 mg twice daily)
Trial: 30142037
Drug: Strips (White
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strips (White Strips, Oral-B)
Trial: 19486269
Drug: oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral and denture hygiene instructions
Trial: 19486269
Drug: instructions associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: instructions associated with the home use of a disclosing agent (1% neutral red)
Trial: 15682849
Drug: Tc‐99m ethylenedicysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m ethylenedicysteine (3.7 MBq/kg body weight) and furosemide at an appropriate dose administered intravenously
Trial: 11568738
Drug: High-dose UVA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UVA1 phototherapy (<=130 J/cm2)
Trial: 11568738
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1 phototherapy (half the dose of high-dose)
Trial: 2594037
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (3000 cGy of electron-beam radiation + parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine)
Trial: 2594037
Drug: Sequential topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential topical treatment
Trial: 2594037
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy and Sequential topical treatment
Trial: 4804456
Drug: Diabetics not
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetics not on any form of treatment
Trial: 31409915
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg in addition to baseline dose of statin
Trial: 29020936
Drug: Staggered sugammadex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staggered sugammadex (1 mg/kg before extubation and 1 mg/kg after extubation)
Trial: 29020936
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus sugammadex (2 mg/kg)
Trial: 29020936
Drug: Neostigmine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.02 mg/kg with glycopyrrolate)
Trial: 23455877
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment (both with and without counseling)